Advance for Laboratories has published a new feature article on Translational Software’s partnership with Inova Health System to provide PGx testing for newborns through Inova’s MediMap PGx test:
Pharmacogenetics for Newborns
One-time test for infants can provide actionable results throughout their lifetimes.
July 18, 2016
By Valerie Neff Newitt
…The mission at hand is to integrate genomic information at the point of birth to personalize patient treatment and improve health outcomes as life stretches forward. In order to accomplish that goal, [Inova launched] MediMap, a pharmacogenomics test, in February.
…Parents of newborns have been extremely enthusiastic about the program, said Ben Solomon, MD, chief, division of medical genomics at ITMI.
…Solomon said the overall goal of the initiative is to use new genetic and genomic technologies and knowledge to better take care of patients. “For example, tens of thousands of children each year are at risk for adverse reactions (some potentially lethal) from codeine because of differences in drug metabolism. By testing for this, we hope to avoid these problems. The program is new, so it’s early to measure outcomes.”
Don Rule, CEO of TSI, commented that, to their credit, Inova is an early adopter of PGx. While medication issues are relatively rare early in life, Rule commented, “When they occur, they can be critically important.”
As these test results follow individuals into the fullness of life, the importance to their health status may become increasingly clear. Rule noted, “There are a growing number of studies that have shown that guiding prescription choice with an understanding of a patient’s genetic factors can not only improve patients’ well-being by avoiding trial-and-error prescribing, but also prevent repetitive and unnecessary treatment by anticipating which medications will not be effective. When physicians can closely tailor personalized treatment based on a patient’s genetic profile, they can choose safer and more effective therapies that result in better patient outcomes at improved cost.”